Cargando…
A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay
BACKGROUND: Since 2020 SARS-CoV-2 spreads pandemically, infecting more than 119 million people, causing >2·6 million fatalities. Symptoms of SARS-CoV-2 infection vary greatly, ranging from asymptomatic to fatal. Different populations react differently to the disease, making it very hard to track...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320407/ https://www.ncbi.nlm.nih.gov/pubmed/34333234 http://dx.doi.org/10.1016/j.ebiom.2021.103502 |
_version_ | 1783730642186403840 |
---|---|
author | Beyerl, Jessica Rubio-Acero, Raquel Castelletti, Noemi Paunovic, Ivana Kroidl, Inge Khan, Zohaib N. Bakuli, Abhishek Tautz, Andreas Oft, Judith Hoelscher, Michael Wieser, Andreas |
author_facet | Beyerl, Jessica Rubio-Acero, Raquel Castelletti, Noemi Paunovic, Ivana Kroidl, Inge Khan, Zohaib N. Bakuli, Abhishek Tautz, Andreas Oft, Judith Hoelscher, Michael Wieser, Andreas |
author_sort | Beyerl, Jessica |
collection | PubMed |
description | BACKGROUND: Since 2020 SARS-CoV-2 spreads pandemically, infecting more than 119 million people, causing >2·6 million fatalities. Symptoms of SARS-CoV-2 infection vary greatly, ranging from asymptomatic to fatal. Different populations react differently to the disease, making it very hard to track the spread of the infection in a population. Measuring specific anti-SARS-CoV-2 antibodies is an important tool to assess the spread of the infection or successful vaccinations. To achieve sufficient sample numbers, alternatives to venous blood sampling are needed not requiring medical personnel or cold-chains. Dried-blood-spots (DBS) on filter-cards have been used for different studies, but not routinely for serology. METHODS: We developed a semi-automated protocol using self-sampled DBS for SARS-CoV-2 serology. It was validated in a cohort of matched DBS and venous-blood samples (n = 1710). Feasibility is demonstrated with two large serosurveys with 10247 company employees and a population cohort of 4465 participants. FINDINGS: Sensitivity and specificity reached 99·20% and 98·65%, respectively. Providing written instructions and video tutorials, 99·87% (4465/4471) of the unsupervised home sampling DBS cards could be analysed. INTERPRETATION: DBS-sampling is a valid and highly reliable tool for large scale serosurveys. We demonstrate feasibility and accuracy with a large validation cohort including unsupervised home sampling. This protocol might be of big importance for surveillance in resource-limited settings, providing low-cost highly accurate serology data. FUNDING: Provided by Bavarian State Ministry of Science and the Arts, LMU University-Hospital; Helmholtz-Centre-Munich, German Ministry for Education and Research (project01KI20271); University of Bonn; University of Bielefeld; the Medical Biodefense Research Program of Bundeswehr-Medical-Service; Euroimmun, RocheDiagnostics provided discounted kits and machines |
format | Online Article Text |
id | pubmed-8320407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83204072021-07-29 A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay Beyerl, Jessica Rubio-Acero, Raquel Castelletti, Noemi Paunovic, Ivana Kroidl, Inge Khan, Zohaib N. Bakuli, Abhishek Tautz, Andreas Oft, Judith Hoelscher, Michael Wieser, Andreas EBioMedicine Research Paper BACKGROUND: Since 2020 SARS-CoV-2 spreads pandemically, infecting more than 119 million people, causing >2·6 million fatalities. Symptoms of SARS-CoV-2 infection vary greatly, ranging from asymptomatic to fatal. Different populations react differently to the disease, making it very hard to track the spread of the infection in a population. Measuring specific anti-SARS-CoV-2 antibodies is an important tool to assess the spread of the infection or successful vaccinations. To achieve sufficient sample numbers, alternatives to venous blood sampling are needed not requiring medical personnel or cold-chains. Dried-blood-spots (DBS) on filter-cards have been used for different studies, but not routinely for serology. METHODS: We developed a semi-automated protocol using self-sampled DBS for SARS-CoV-2 serology. It was validated in a cohort of matched DBS and venous-blood samples (n = 1710). Feasibility is demonstrated with two large serosurveys with 10247 company employees and a population cohort of 4465 participants. FINDINGS: Sensitivity and specificity reached 99·20% and 98·65%, respectively. Providing written instructions and video tutorials, 99·87% (4465/4471) of the unsupervised home sampling DBS cards could be analysed. INTERPRETATION: DBS-sampling is a valid and highly reliable tool for large scale serosurveys. We demonstrate feasibility and accuracy with a large validation cohort including unsupervised home sampling. This protocol might be of big importance for surveillance in resource-limited settings, providing low-cost highly accurate serology data. FUNDING: Provided by Bavarian State Ministry of Science and the Arts, LMU University-Hospital; Helmholtz-Centre-Munich, German Ministry for Education and Research (project01KI20271); University of Bonn; University of Bielefeld; the Medical Biodefense Research Program of Bundeswehr-Medical-Service; Euroimmun, RocheDiagnostics provided discounted kits and machines Elsevier 2021-07-29 /pmc/articles/PMC8320407/ /pubmed/34333234 http://dx.doi.org/10.1016/j.ebiom.2021.103502 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Beyerl, Jessica Rubio-Acero, Raquel Castelletti, Noemi Paunovic, Ivana Kroidl, Inge Khan, Zohaib N. Bakuli, Abhishek Tautz, Andreas Oft, Judith Hoelscher, Michael Wieser, Andreas A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title | A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title_full | A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title_fullStr | A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title_full_unstemmed | A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title_short | A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay |
title_sort | dried blood spot protocol for high throughput analysis of sars-cov-2 serology based on the roche elecsys anti-n assay |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320407/ https://www.ncbi.nlm.nih.gov/pubmed/34333234 http://dx.doi.org/10.1016/j.ebiom.2021.103502 |
work_keys_str_mv | AT beyerljessica adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT rubioaceroraquel adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT castellettinoemi adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT paunovicivana adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT kroidlinge adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT khanzohaibn adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT bakuliabhishek adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT tautzandreas adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT oftjudith adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT hoelschermichael adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT wieserandreas adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT adriedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT beyerljessica driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT rubioaceroraquel driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT castellettinoemi driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT paunovicivana driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT kroidlinge driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT khanzohaibn driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT bakuliabhishek driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT tautzandreas driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT oftjudith driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT hoelschermichael driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT wieserandreas driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay AT driedbloodspotprotocolforhighthroughputanalysisofsarscov2serologybasedontherocheelecsysantinassay |